Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice

Alimentary Pharmacology and Therapeutics

Volumn 44, Issue 4, 2016, Pages 400-410

  Backus, L I ^a   Belperio, P S ^a   Shahoumian, T A ^a   Loomis, T P ^a   Mole, L A ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; LEDIPASVIR PLUS SOFOSBUVIR; RIBAVIRIN; VIRUS RNA;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BODY MASS; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; INTENTION TO TREAT ANALYSIS; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT DURATION;

EID: 85027954287     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13696     Document Type: Article

References (27)

1. Sulkowski MS, Vargas HE, Di Bisceglie AM, et al. Effectiveness of simeprevir plus sofosbuvir with or without ribavirin in real-world patients with HCV genotype 1 infection. Gastroenterology 2016; 150: 419–29.
2. Brown RS Jr, O'Leary JG, Reddy KR, et al. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: real-world experience from the hepatitis C therapeutic registry and research network. Liver Transpl 2016; 22: 24–33.
3. Martinello M, Dore GJ. Editorial commentary: interferon-free hepatitis C treatment efficacy from clinical trials will translate to “real-world” outcomes. Clin Infect Dis 2016; 62: 927–8.
4. Walker DR, Pedrosa MC, Manthena SR, Patel N, Marx SE. Early view of the effectiveness of new direct-ccting antiviral (DAA) regimens in patients with hepatitis C virus (HCV). Adv Ther 2015; 32: 1117–27.
5. Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans. Aliment Pharmacol Ther 2015; 42: 559–73.
6. Shiffman ML, James AM, Long AG, Alexander PC. Treatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and/or ribavirin. Am J Gastroenterol 2015; 110: 1179–85.
7. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889–98.
8. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483–93.
9. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879–88.
10. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1594–603.
11. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1604–14.
12. Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 2014; 147: 359–65.
13. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370: 1983–92.
14. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370: 1973–82.
15. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States 1999 through 2002. Ann Intern Med 2006; 144: 705–14.
16. Backus LI, Belperio PS, Loomis TP, Yip GH, Mole LA. Hepatitis C virus screening and prevalence among US veterans in Department of Veterans Affairs care. JAMA Intern Med 2013; 173: 1549–52.
17. Belperio PS, Backus LI, Ross D, Neuhauser MM, Mole LA. A population approach to disease management: hepatitis C direct-acting antiviral use in a large health care system. J Manag Care Pharm 2014; 20: 533–40.
18. Backus LI, Gavrilov S, Loomis TP, et al. Clinical Case Registries: simultaneous local and national disease registries for population quality management. J Am Med Inform Assoc 2009; 16: 775–83.
19. Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Real world effectiveness of ledipasvir/sofosbuvir in 4365 treatment-naïve genotype 1 hepatitis C infected patients. Hepatology 2016; doi: 10.1002/hep.28625 [Epub ahead of print]
20. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and Fibrotest. Hepatology 2007; 46: 32–6.
21. Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med 2013; 158: 807–20.
22. Wilder JM, Jeffers LJ, Ravendhran N, et al. Safety and efficacy of ledipasvir-sofosbuvir in African Americans with hepatitis C virus infection: a retrospective analysis of phase 3 data. Hepatology 2016; 63: 437–44.
23. Ioannou GN, Beste LA, Green PK. Similar effectiveness of boceprevir and telaprevir treatment regimens for hepatitis C virus infection, based on a nationwide study of Veterans. Clin Gastroenterol Hepatol 2014; 12: 1371–80.
24. Sterling RK, Kuo A, Rustgi VK, et al. Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir. Aliment Pharmacol Ther 2015; 41: 671–85.
25. Backus LI, Belperio PS, Shahoumian TA, Cheung R, Mole LA. Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort. Aliment Pharmacol Ther 2014; 39: 93–103.
26. Harvoni (Ledipasvir and Sofosbuvir) Tablet Product Information. Foster City, CA: Gilead Sciences, Inc, November 2015.
27. AASLD/IDSA HCV Guidance Panel. Chung RT, Davis GL, Jensen DM, et al. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015; 62: 932–54. http://www.hcvguidelines.org/full-report-viewAASLDguidelines.